XOMA 213

Drug Profile

XOMA 213

Alternative Names: LFA102; XOMA-213

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator XOMA
  • Developer Novartis; XOMA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prolactinoma
  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 18 May 2016 XOMA initiates enrolment in a phase II trial for Suppression of lactation in Spain (EudraCT2015-005751-27; 9198651)
  • 14 Mar 2016 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Late-stage disease) in Japan (IV)
  • 14 Mar 2016 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Late-stage disease) in Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top